CN113248506A - 取代的氨基嘌呤化合物、其组合物及其治疗方法 - Google Patents

取代的氨基嘌呤化合物、其组合物及其治疗方法 Download PDF

Info

Publication number
CN113248506A
CN113248506A CN202110381676.XA CN202110381676A CN113248506A CN 113248506 A CN113248506 A CN 113248506A CN 202110381676 A CN202110381676 A CN 202110381676A CN 113248506 A CN113248506 A CN 113248506A
Authority
CN
China
Prior art keywords
amino
substituted
unsubstituted
pyran
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202110381676.XA
Other languages
English (en)
Chinese (zh)
Inventor
马修·亚历山大
索哥利·巴曼亚
约翰·弗雷德里克·博伊兰
约书亚·汉森
黄德华
罗伯特·哈伯德
布兰登·杰菲
吉姆·莱斯滕
迈赫兰·穆贾达姆
拉杰·K·拉赫加
希瑟·雷蒙
金佰利·施华兹
玛丽安·斯洛斯
艾杜亚度·托里斯
塔姆·明·特朗
徐水蟾
赵晶晶
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Signal Pharmaceuticals LLC
Original Assignee
Signal Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Signal Pharmaceuticals LLC filed Critical Signal Pharmaceuticals LLC
Publication of CN113248506A publication Critical patent/CN113248506A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/50—Three nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN202110381676.XA 2014-10-06 2015-10-05 取代的氨基嘌呤化合物、其组合物及其治疗方法 Pending CN113248506A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462060339P 2014-10-06 2014-10-06
US62/060,339 2014-10-06
CN201580065272.2A CN107001372B (zh) 2014-10-06 2015-10-05 取代的氨基嘌呤化合物、其组合物及其治疗方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201580065272.2A Division CN107001372B (zh) 2014-10-06 2015-10-05 取代的氨基嘌呤化合物、其组合物及其治疗方法

Publications (1)

Publication Number Publication Date
CN113248506A true CN113248506A (zh) 2021-08-13

Family

ID=55632334

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202110381676.XA Pending CN113248506A (zh) 2014-10-06 2015-10-05 取代的氨基嘌呤化合物、其组合物及其治疗方法
CN201580065272.2A Active CN107001372B (zh) 2014-10-06 2015-10-05 取代的氨基嘌呤化合物、其组合物及其治疗方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201580065272.2A Active CN107001372B (zh) 2014-10-06 2015-10-05 取代的氨基嘌呤化合物、其组合物及其治疗方法

Country Status (28)

Country Link
US (8) US9512124B2 (enExample)
EP (2) EP3822274B1 (enExample)
JP (4) JP6884701B2 (enExample)
KR (2) KR20230035424A (enExample)
CN (2) CN113248506A (enExample)
AR (2) AR102171A1 (enExample)
AU (2) AU2015328414B2 (enExample)
CA (1) CA2963639C (enExample)
CL (1) CL2017000820A1 (enExample)
CO (1) CO2017003838A2 (enExample)
CY (1) CY1124173T1 (enExample)
DK (1) DK3204386T3 (enExample)
EA (1) EA201790779A1 (enExample)
EC (1) ECSP17026210A (enExample)
ES (2) ES2871142T3 (enExample)
HR (1) HRP20210656T1 (enExample)
HU (1) HUE054694T2 (enExample)
IL (2) IL251566B (enExample)
LT (1) LT3204386T (enExample)
MX (2) MX388321B (enExample)
PL (1) PL3204386T3 (enExample)
PT (1) PT3204386T (enExample)
RS (1) RS61884B1 (enExample)
SG (2) SG10202009598VA (enExample)
SI (1) SI3204386T1 (enExample)
SM (1) SMT202100302T1 (enExample)
TW (1) TW201629063A (enExample)
WO (1) WO2016057370A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114478326A (zh) * 2022-01-21 2022-05-13 安徽宁亿泰科技有限公司 一种苯嘧磺草胺关键中间体的合成方法

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3204386T3 (da) * 2014-10-06 2021-05-25 Signal Pharm Llc Substituerede aminopurinforbindelser, sammensætninger deraf og fremgangsmåder til behandling dermed
US9513297B2 (en) 2014-12-16 2016-12-06 Signal Pharmaceuticals, Llc Methods for measurement of inhibition of c-Jun N-terminal kinase in skin
EP3250557B1 (en) 2015-01-29 2024-11-20 Signal Pharmaceuticals, LLC Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
US10112944B2 (en) 2015-03-18 2018-10-30 Bristol-Myers Squibb Company Heterocyclic compounds useful as inhibitors of TNF
ES2797805T3 (es) 2015-03-18 2020-12-03 Bristol Myers Squibb Co Compuestos heterocíclicos tricíclicos sustituidos
ES2797685T3 (es) 2015-03-18 2020-12-03 Bristol Myers Squibb Co Compuestos heterocíclicos tricíclicos útiles como inhibidores de TNF
EP3325432B1 (en) 2015-07-24 2020-09-02 Celgene Corporation Methods of synthesis of (1r,2r,5r)-5-amino-2-methylcyclohexanol hydrochloride and intermediates useful therein
EA201890421A1 (ru) 2015-08-03 2018-07-31 Бристол-Маерс Сквибб Компани Циклические соединения, пригодные в качестве модуляторов tnf-альфа
US10576085B2 (en) * 2016-04-01 2020-03-03 Signal Pharmaceuticals, Llc Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
MX379439B (es) * 2016-04-01 2025-03-10 Signal Pharm Llc Formas sólidas de (1s,4s)-4-(2-(((3s,4r)-3-fluorotetrahidro-2h-piran-4-il)amino)-8-((2,4,6-triclorofenil)amino)-9h-purin-9-il)-1-metilciclohexano-1-carboxamida y métodos para utilizarlas.
US10010555B2 (en) 2016-06-02 2018-07-03 Celgene Corporation Animal and human anti-trypanosomonal and anti-leishmania agents
ES2926149T3 (es) * 2016-06-02 2022-10-24 Celgene Corp Agentes antipalúdicos animales y humanos
MX2020003620A (es) 2017-10-04 2020-10-28 Celgene Corp Composiciones y métodos para usar cis-4-[2-{[(3s,4r)-3-fluorooxan- 4-il]amino}-8-(2,4,6-tricloroanilino)-9h-purin-9-il]-1-etilcicloh exano-1-carboxamida.
EP3692041A1 (en) * 2017-10-04 2020-08-12 Celgene Corporation Processes for the preparation of cis-4 [2-{(3s.4r)-3-fluorooxan-4-yl]amino)-8-(2,4,6-trichloroanilino)-9h-purin-9-yl]-1-methylcyclohexane-1-carboxamide
CN115916747A (zh) * 2020-07-01 2023-04-04 四川海思科制药有限公司 一种并环杂环衍生物及其在医药上的应用
TW202329937A (zh) 2021-12-03 2023-08-01 美商英塞特公司 雙環胺ck12抑制劑
US12084453B2 (en) 2021-12-10 2024-09-10 Incyte Corporation Bicyclic amines as CDK12 inhibitors
CN117964497B (zh) * 2024-01-26 2026-03-31 江西凯信生物医药有限公司 一种3,3-二氟环戊胺盐酸盐的合成方法
CN121758295A (zh) * 2024-09-30 2026-03-31 青岛清原化合物有限公司 一种亚氨基芳基类化合物及中间体的制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030191086A1 (en) * 1999-01-26 2003-10-09 Ustav Experimentalni Botaniky Av Cr Substituted nitrogen heterocyclic derivatives and pharmaceutical use thereof
CN101478972A (zh) * 2006-04-26 2009-07-08 西格诺药品有限公司 卤代芳基取代的氨基嘌呤、其组合物,和将其用于治疗的方法
TW201305167A (zh) * 2010-10-25 2013-02-01 Signal Pharm Llc 使用經鹵芳基取代之胺基嘌呤的治療、改善及預防方法
CN103087066A (zh) * 2005-01-13 2013-05-08 西格诺药品有限公司 卤代芳基取代的氨基嘌呤、其组合物及其治疗方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL99699A (en) 1990-10-10 2002-04-21 Autoimmune Inc Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
FI109088B (fi) 1997-09-19 2002-05-31 Leiras Oy Tabletti ja menetelmä sen valmistamiseksi
US7672705B2 (en) * 2004-07-19 2010-03-02 Resonant Medical, Inc. Weighted surface-to-surface mapping
US7759342B2 (en) 2005-01-13 2010-07-20 Signal Pharmaceuticals, Llc Methods of treatment and prevention using haloaryl substituted aminopurines
WO2007062338A2 (en) 2005-11-18 2007-05-31 Astrazeneca Ab Solid formulations
TWI398252B (zh) 2006-05-26 2013-06-11 諾華公司 吡咯并嘧啶化合物及其用途
NZ576347A (en) 2006-10-27 2011-10-28 Signal Pharm Llc Solid forms comprising 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol, compositions thereof, and use therewith
DK2279731T3 (da) 2008-04-23 2013-03-18 Farmasierra Mfg S L Forbedret farmaceutisk sammensætning, som indeholder ibuprofen og codein
WO2011071491A1 (en) 2009-12-09 2011-06-16 Signal Pharmaceuticals, Llc Isotopologues of 4-[9-(tetrahydro-furan-3-yl)-8-(2, 4, 6- trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol
US8603527B2 (en) 2010-10-25 2013-12-10 Signal Pharmaceuticals, Llc Pharmaceutical formulations of a substituted diaminopurine
WO2014172616A2 (en) 2013-04-18 2014-10-23 President And Fellows Of Harvard College Methods, compositions and kits for promoting motor neuron survival and treating and diagnosing neurodegenerative disorders
GB201321737D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
DK3204386T3 (da) 2014-10-06 2021-05-25 Signal Pharm Llc Substituerede aminopurinforbindelser, sammensætninger deraf og fremgangsmåder til behandling dermed
MX379439B (es) 2016-04-01 2025-03-10 Signal Pharm Llc Formas sólidas de (1s,4s)-4-(2-(((3s,4r)-3-fluorotetrahidro-2h-piran-4-il)amino)-8-((2,4,6-triclorofenil)amino)-9h-purin-9-il)-1-metilciclohexano-1-carboxamida y métodos para utilizarlas.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030191086A1 (en) * 1999-01-26 2003-10-09 Ustav Experimentalni Botaniky Av Cr Substituted nitrogen heterocyclic derivatives and pharmaceutical use thereof
CN103087066A (zh) * 2005-01-13 2013-05-08 西格诺药品有限公司 卤代芳基取代的氨基嘌呤、其组合物及其治疗方法
CN101478972A (zh) * 2006-04-26 2009-07-08 西格诺药品有限公司 卤代芳基取代的氨基嘌呤、其组合物,和将其用于治疗的方法
TW201305167A (zh) * 2010-10-25 2013-02-01 Signal Pharm Llc 使用經鹵芳基取代之胺基嘌呤的治療、改善及預防方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
VÉRONIQUE PLANTEVIN KRENITSKY等: "Aminopurine based JNK inhibitors for the prevention of ischemia reperfusion injury" *
VÉRONIQUE PLANTEVIN KRENITSKY等: "Aminopurine based JNK inhibitors for the prevention of ischemia reperfusion injury", 《BIOORGANIC & MEDICINAL CHEMISTRY LETTERS》, vol. 22, pages 1427 - 1432, XP028886999, DOI: 10.1016/j.bmcl.2011.12.028 *
VÉRONIQUE PLANTEVIN KRENITSKY等: "Discovery of CC-930, an orally active anti-fibrotic JNK inhibitor", 《BIOORGANIC & MEDICINAL CHEMISTRY LETTERS》, vol. 22, pages 1433 - 1438, XP028886996, DOI: 10.1016/j.bmcl.2011.12.027 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114478326A (zh) * 2022-01-21 2022-05-13 安徽宁亿泰科技有限公司 一种苯嘧磺草胺关键中间体的合成方法
CN114478326B (zh) * 2022-01-21 2023-10-03 安徽宁亿泰科技有限公司 一种苯嘧磺草胺关键中间体的合成方法

Also Published As

Publication number Publication date
JP7196270B2 (ja) 2022-12-26
SI3204386T1 (sl) 2021-08-31
US20190091230A1 (en) 2019-03-28
AR102171A1 (es) 2017-02-08
EP3204386A1 (en) 2017-08-16
US20170296546A1 (en) 2017-10-19
AR128748A2 (es) 2024-06-12
AU2015328414B2 (en) 2020-03-19
JP2022033858A (ja) 2022-03-02
US20170042902A1 (en) 2017-02-16
CA2963639C (en) 2023-07-04
NZ767954A (en) 2024-02-23
PL3204386T3 (pl) 2021-09-20
DK3204386T3 (da) 2021-05-25
IL277069A (en) 2020-10-29
IL251566B (en) 2020-09-30
TW201629063A (zh) 2016-08-16
PT3204386T (pt) 2021-05-31
EP3204386B1 (en) 2021-03-03
AU2020201486A1 (en) 2020-03-19
RS61884B1 (sr) 2021-06-30
US10940152B2 (en) 2021-03-09
US20160096841A1 (en) 2016-04-07
NZ730753A (en) 2024-02-23
JP2023027269A (ja) 2023-03-01
EP3822274A1 (en) 2021-05-19
CL2017000820A1 (es) 2017-12-15
CY1124173T1 (el) 2022-05-27
KR20170063740A (ko) 2017-06-08
US10398700B2 (en) 2019-09-03
US11590139B2 (en) 2023-02-28
JP6884701B2 (ja) 2021-06-09
JP6987823B2 (ja) 2022-01-05
US20210128565A1 (en) 2021-05-06
KR20230035424A (ko) 2023-03-13
WO2016057370A1 (en) 2016-04-14
US20190336507A1 (en) 2019-11-07
HRP20210656T1 (hr) 2021-07-23
US20230158035A1 (en) 2023-05-25
IL277069B (en) 2022-05-01
CA2963639A1 (en) 2016-04-14
SG11201702759XA (en) 2017-05-30
SG10202009598VA (en) 2020-10-29
CN107001372A (zh) 2017-08-01
SMT202100302T1 (it) 2021-07-12
LT3204386T (lt) 2021-07-12
ES2871142T3 (es) 2021-10-28
AU2015328414A1 (en) 2017-04-27
MX2021014531A (es) 2022-01-06
MX388321B (es) 2025-03-19
AU2020201486B2 (en) 2021-07-08
JP2017530199A (ja) 2017-10-12
ES2980464T3 (es) 2024-10-01
IL251566A0 (en) 2017-05-29
MX2017004600A (es) 2017-06-30
EP3204386A4 (en) 2018-04-18
EA201790779A1 (ru) 2017-09-29
HUE054694T2 (hu) 2021-09-28
EP3822274B1 (en) 2024-03-06
CO2017003838A2 (es) 2017-07-11
US20200237768A1 (en) 2020-07-30
US10646493B2 (en) 2020-05-12
US9512124B2 (en) 2016-12-06
US9737541B2 (en) 2017-08-22
CN107001372B (zh) 2021-04-27
KR102504849B1 (ko) 2023-03-02
JP2020033352A (ja) 2020-03-05
ECSP17026210A (es) 2017-05-31
US10149849B2 (en) 2018-12-11
BR112017006998A2 (pt) 2018-01-16

Similar Documents

Publication Publication Date Title
CN107001372B (zh) 取代的氨基嘌呤化合物、其组合物及其治疗方法
EA031671B1 (ru) Твердые формы 2-(трет-бутиламино)-4-((1r,3r,4r)-3-гидрокси-4-метилциклогексиламино)пиримидин-5-карбоксамида, его композиции и способы его применения
US10420772B2 (en) Animal and human anti-trypanosomonal and anti-leishmania agents
HK1241852B (en) Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
BR112017006998B1 (pt) Composto de aminopurina substituído, composição farmacêutica compreendendo o mesmo, uso e método para preparar o referido composto e métodos in vitro e ex vivo de inibição de quinase

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210813

WD01 Invention patent application deemed withdrawn after publication